has received a Certificate of GMP Compliance from the Malta Medicines Authority for its Daman manufacturing facility, valid for 3 years starting December 9, 2025. The certification validates the facility's adherence to European Union Good Manufacturing Practice standards following a successful inspection conducted on the same date. The pharmaceutical company informed stock exchanges about this regulatory milestone on March 20, 2026. Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations.